 Germany’s legal environment: Germany is a democratic country with a constitution.

In
civil matters, foreign nationals receive the same treatment as citizens. Legal language is
Germany. The constitution of May 1949, also known as the Fundamental Law for the Federal
Republic of Germany and it is the primary source of law. The legal system of the country is
based on a civil law system that combines historical principles and judicial modifications of
various legislative actions by the Federal Constitutional Court. The general partner is
normally the only entirely responsible party in a merger, with the other parties having only
some of the liability issues. There are no upper caps on the amount of money that can be
shared in these projects, nor are there any licensing procedures that must be followed to keep
the agreements going. German antitrust laws apply to joint venture.

 Legal environment with company’s operations- The United Kingdom granted Pfizer-
vaccine BioNTech's emergency use authorization (contract law) on December 2, 2020,
making it the first country to authorize a COVID-19 vaccine." Subject to regulatory (legal)
approval, the agreement provides for a supply of 200 million doses with the option to request
an additional 100 million doses, with deliveries expected to begin by the end of 2020. Based
on current estimates, the vaccine supply for the EU will be provided by BioNTech's
manufacturing sites in Germany and Pfizer's manufacturing site in Belgium. In 2021, the
companies estimate that they will deliver up to 1.3 billion doses globally. Pfizer started a
rolling submission to the European Medicines Agency (EMA) in October, and it intends to
keep in touch with the agency on a regular basis to share the findings of their ongoing Phase
3 trial.

 Cost: After signing a contract for 100 million doses at a cost of $1.95 billion, or around €16
per dose.

 Risk: The vaccination programs in Germany are in danger, according to Germany

governments, after Pfizer, the world's largest pharmaceutical company, declared a temporary
halt in deliveries of its Covid-19 vaccine after that Germany law provide adequate protection
to solve this matter.

 Opportunities: A new opportunity for the development of the COVID-19 vaccine produced
by BioNTech and Pfizer, has also been approved. The factory, which is located in Marburg,
Germany, will manufacture both the active substance and the finished product.
https://uk.practicallaw.thomsonreuters.com/w-013-1932?
transitionType=Default&contextData=(sc.Default)&firstPage=true

https://www.dw.com/en/biontech-pfizer-originally-demanded-54-per-vaccine-dose/a-56620748

https://uk.practicallaw.thomsonreuters.com/w-013-1932?
transitionType=Default&contextData=(sc.Default)&firstPage=true

https://santandertrade.com/en/portal/establish-overseas/germany/legal-
environment#:~:text=Germany%20is%20a%20constitutional%20state.&text=The%20country's
%20judicial%20system%20is,obligatory%20jurisdiction%20of%20the%20ICJ

https://www.irishtimes.com/news/world/europe/eu-states-warn-of-risks-to-vaccination-credibility-as-
pfizer-slows-supplies-1.4460340

https://www.ema.europa.eu/en/news/increase-vaccine-manufacturing-capacity-supply-covid-19-
vaccines-astrazeneca-biontechpfizer-moderna